文献速递MDS 与骨髓增殖性肿瘤

真性红细胞增多症患者继发恶性肿瘤的患病率、发病率及危险因素:一项真实世界研究

Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: a real-world study.
PubMed 文献 · Blood Adv · 2026-01-01

indexed后36%患者至少发生1种非PV恶性肿瘤(随访4.3年),最常见为非血液系统皮肤癌(包括黑色素瘤和非黑色素瘤皮肤癌)。暴露于羟基脲者新发黑色素瘤或非黑色素瘤皮肤癌的复合终点发生率约为仅治疗性放血者的近2倍;校正混杂因素后,羟基脲暴露≥4周者发生新发黑色素瘤或非黑色素瘤皮肤癌的风险仍较高(HR 1.33,95%CI 1.17-1.50)。

要点

  • PV患者继发恶性肿瘤常见, indexed后36%发生非PV恶性肿瘤,以皮肤癌为主。
  • 羟基脲暴露≥4周与新发黑色素瘤或非黑色素瘤皮肤癌风险升高相关(HR 1.33)。
  • 老年、既往皮肤癌史及index前使用降细胞药物是皮肤癌最强危险因素。

核心结论

  • PV患者继发恶性肿瘤(尤其皮肤癌)负担较高,羟基脲暴露可能与新发黑色素瘤或非黑色素瘤皮肤癌风险升高相关。

主要发现

  • index后36%患者至少发生1种非PV恶性肿瘤,随访时间4.3年。
  • 最常见的非血液系统恶性肿瘤为皮肤癌,包括黑色素瘤和非黑色素瘤皮肤癌(NMSC)。
  • 任何时间暴露于羟基脲者新发黑色素瘤或NMSC复合终点发生率约为仅治疗性放血者的近2倍。
  • 观察期内黑色素瘤或NMSC的最强危险因素包括年龄较大、既往皮肤癌史及index前使用降细胞药物。
  • 校正潜在混杂因素后,羟基脲暴露≥4周者较无羟基脲暴露者新发黑色素瘤或NMSC风险更高(HR 1.33,95%CI 1.17-1.50)。

临床怎么用

  • PV患者应关注继发恶性肿瘤风险,尤其是皮肤癌的监测。
  • 使用羟基脲者需权衡皮肤癌风险,定期皮肤检查可能有益。

局限性

  • 该发现可能受不同患者群体疾病负担差异影响,需进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with the primary myeloproliferative neoplasm polycythemia vera (PV) are at risk of the development of secondary malignancies, including skin cancers. This real-world, retrospective cohort study used Optum Market Clarity electronic health record data and linked medical and pharmacy claims from 70 million patients in the United States between 1 January 2007 and 31 December 2019 to assess the frequency of secondary malignancies in patients with a new or established diagnosis of PV (N = 82 947 with ≥1 PV diagnosis; the final cohort for this study included 20 089 patients) and the association of these cancers with patient characteristics and PV treatment. After indexing, 36% of patients had at least 1 non-PV malignancy (follow-up duration, 4.3 years). The most common nonhematologic malignancies were skin cancers, including melanoma and nonmelanoma skin cancer (NMSC). The incidence rate for a composite outcome of new-onset melanoma or NMSC was nearly twofold higher in patients who were exposed to hydroxyurea at any time than in those who were exposed to therapeutic phlebotomy alone. The strongest risk factors for occurrence of melanoma or NMSC in the observation period included older age, previous history of skin cancer, and preindex period use of cytoreductive medications. After controlling for potential confounders, a higher likelihood of developing new-onset melanoma or NMSC was observed in patients who received ≥4 weeks of hydroxyurea exposure vs those with no hydroxyurea exposure (hazard ratio, 1.33; 95% confidence interval, 1.17-1.50). This finding, which may have been influenced by different disease burdens among this diverse patient population, warrants further exploration.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pemmaraju N, Markova A, Masarova L, et al. Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: a real-world study. Blood Adv. 2026. PMID: 42054546. doi:10.1182/bloodadvances.2025019349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。